Merus leads biotech with its innovative antibody platforms, strong financials, and promising petosemtamab targeting cancer.

Bispecific antibodies have become component in the arsenal of treatments for hematologic malignancies; management of their side effects is crucial to their success.

A recent study published in Science Translational Medicine introduced a bispecific antibody that effectively neutralizes highly mutated SARS-CoV-2 variants, including XBB.1.5. By combining two ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

Bispecific antibodies first reached patients as cancer treatments, but a growing number of companies are working to expand these therapies to autoimmune diseases. Sanofi is adding a new contender ...

BNT327, a PD L1/VEGF antibody, belongs to a class of next-generation immunotherapies hoping to beat out Keytruda.

Building on this foundation, bispecific and trispecific antibodies have emerged as innovative biologics aimed at simultaneously engaging multiple targets, promising improved efficacy and safety ...

Incorporating Bispecific Antibodies Earlier in Treatment and Improving Access in Underserved Communities EP: 15 . Future Breakthroughs: What’s Next for Bispecific Antibodies in Oncology?

Johnson & Johnson has its first worldwide regulatory approval – in the EU – for Tecvayli, one of two much-anticipated bispecific antibodies the drugmaker has developed for patients with ...

ImmunoPrecise Antibodies has secured a collaboration with an undisclosed “leading biotech” to discover new antibody-drug conjugates and bispecific antibodies to treat cancer. The agreement ...

an anti-CTLA-4 monoclonal antibody; IBI-323, a novel LAG3/PD-L1 bispecific antibody; IBI-363, a potential PD-1/IL-2 bispecific antibody fusion protein; IBI-343, a recombinant anti-CLDN18.2 ...